



LSP Life Sciences Fund N.V.

Annual Report 2022



PricewaterhouseCoopers
Accountants N.V.
For identification
purposes only



EQT
Life Sciences

TABLE OF CONTENTS

PROFILE.....	4
DIRECTOR'S REPORT	6
SUPERVISORY BOARD REPORT	17
KEY FIGURES	18
FINANCIAL STATEMENTS	
BALANCE SHEET on 31 December 2022	20
PROFIT AND LOSS ACCOUNT for the year ended 31 December 2022	21
CASH FLOW STATEMENT for the year ended 31 December 2022	22
SELECTED NOTES TO THE FINANCIAL STATEMENTS.....	23
OTHER INFORMATION	
PROFIT ALLOCATION AND DISTRIBUTION POLICY	42
INDEPENDENT AUDITOR'S REPORT	43
STATEMENT OF THE DEPOSITARY.....	56
RESPONSIBLE INVESTMENT REPORT.....	57

PROFILE

General information

LSP Life Sciences Fund N.V. (the Fund) is a public company with the status of an investment company with variable capital organised and established under the laws of the Netherlands on 18 April 2011. The Fund has its statutory seat in Amsterdam, the Netherlands and is registered at the Trade Register of the Chamber of Commerce in Amsterdam under file number 52545474. The Fund is an open-end investment fund listed on Euronext Amsterdam and its ISIN Code is NL0009756394. The Fund qualifies as a tax-exempt investment fund within the meaning of article 6a of the Dutch corporate income tax act. Accordingly, the Fund is not subject to Dutch corporate income tax.

Investment strategy

The Fund's primary investment objective is to achieve capital appreciation by investing in a diversified, yet concentrated portfolio of publicly listed life sciences companies (including biopharmaceutical, specialist pharmaceutical, medical device, drug delivery, vaccine and diagnostic companies). The majority of the Fund's portfolio will consist of European companies listed on one of the (main) European stock exchanges, with a market capitalization of below Euro 2.5 billion at the time of investment. The Fund Manager believes that in particular this sub-segment of companies – generally referred to as the small- and midcap segment – offers great potential for value growth. Typically, these companies will have developed a suite of innovative technologies that offer benefit over existing technologies and approaches. In addition, these companies have frequently established a product development pipeline that consists of therapeutics that have the potential to offer clinical benefit to a large and/or underserved market. The Fund intends to specifically target those companies that are projected to realize important clinical, regulatory or commercial milestones, value-enhancing partnerships and/or offer M&A potential. By doing so, the Fund expects to benefit from the value increases that frequently accompany the announcement of such milestones, partnerships or M&A transactions.

Fund Governance

The Fund is managed by LSP Advisory B.V. as Alternative Investment Fund Manager (AIFM) and managing director of the Fund. Following the acquisition by EQT of LSP which was effectuated on 28 February 2022, LSP Advisory B.V. is now a wholly owned subsidiary of EQT Life Sciences Group B.V. which in turn has EQT AB, a Swedish public company with a listing on the Nasdaq Stockholm Stock Exchange, as its ultimate parent. In connection with the acquisition, LSP has been rebranded into EQT Life Sciences.

The Fund Manager is responsible for the entire management of the Fund in accordance with the provisions of the Fund's organizational documents and applicable laws. The core investment team of the Fund Manager consists of two individuals - Mark Wegter and Geraldine O'Keeffe – who have complementary investment skills and backgrounds relevant to the Fund's business.

The investment team receives full support from the in-depth industry knowledge of the entire EQT Life Sciences (previously LSP) organization. The Fund Manager is further supported by EQT Life Sciences' established, global

network of advisors and experts who bring specific expertise essential for performing in-depth due diligence on potential and existing investee companies.

The Fund Manager has been granted a license pursuant to Article 2:65 of the Dutch Financial Markets Supervision Act (Wft) by the Netherlands Authority for the Financial Markets on 12 April 2011. With the Alternative Investment Fund Managers Directive (AIFMD) that came into force on 22 July 2014, this license has been converted into an AIFM license by legislative decree.

The Supervisory Board of the Fund comprises of Onno Paymans and Maarten Scholten, who both have relevant expertise on the Fund's business. The principal duties and responsibilities of the Supervisory Board include (i) the supervision of the management of the Fund as performed by the Fund Manager as well as to supervise the general course of affairs of the Fund, and (ii) resolving any conflict-of-interest situation the Fund is involved in. The Supervisory Board also serves as the Audit Committee of the Fund.

RESPONSIBLE INVESTMENT REPORT

Product name: LSP Life Sciences Fund NV

Legal entity identifier: 724500YDP1CL5LKTUK53

Environmental and/or social characteristics

Did this financial product have a sustainable investment objective?

Yes No

<input type="checkbox"/> It made sustainable investments with an environmental objective: __%	<input type="checkbox"/> It promoted Environmental/Social (E/S) characteristics and while it did not have as its objective a sustainable investment, it had a proportion of __% of sustainable investments
<input type="checkbox"/> in economic activities that qualify as environmentally sustainable under the EU Taxonomy	<input type="checkbox"/> with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
<input type="checkbox"/> in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy	<input type="checkbox"/> with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
<input type="checkbox"/> It made sustainable investments with a social objective: __%	<input type="checkbox"/> with a social objective
	<input checked="" type="checkbox"/> It promoted E/S characteristics, but did not make any sustainable investments

To safeguard that the Fund does not invest in companies that significantly harm any sustainable investment objective, the Fund has stringent exclusions criteria. The Fund excludes companies from its investment universe on the basis of environmentally or socially controversial products which includes amongst others the production of and trade in tobacco and distilled alcohol beverages; production of and trade in weapons and ammunition of any kind; the exploitation, supply and production of and trade in oil and gas; casinos and equivalent enterprises.